The Physician Data Query Backfile (PDQB) contains information on clinical trials that are no longer accepting patients. These records are no longer contained in the Physician Data Query Protocol file. All protocols contain detailed information on objectives, patient entry criteria and details of the treatment regimen. Each record retains the same information it had while in the active protocol file, with two exceptions: only the name of the lead investigator and the lead organization are retained, and a closing date is added.
The following alphabetical list provides the two-letter label, the relevant alias, and an example for each PDQ Backfile field.
===== ============ Label Name/Example ===== ============ ab Abstract [Word Indexed] example: neuropsychiatric.ab. an Accession Number [Word and Phrase Indexed] example 1: 001438.an. example 2: pdqp-001438.an. cn Cancer Name [Word Indexed] example: small cell lung.cn. di Drug Identifiers [Word Indexed] example: arabinoside.di. id Identification Number [Phrase Indexed] example: clb-9362.id. lo Lead Organizations [Word Indexed] example 1: ohio.lo. example 2: herbert maurer.lo. ph Phase [Word Indexed] example: phase iii.ph. pr Protocol Name [Word Indexed] example: small cell lung.pr. ps Protocol Status [Word Indexed] example 1: "930528".ps. example 2: "93$4".ps. tm Therapy Modality [Word Indexed] example: radiation therapy.tm. tx Detail of Protocol [Word Indexed] example: randomized study.tx. ty Type of Protocol [Word Indexed] example: clinical trial.ty. up Update Code [Phrase Indexed] example: 9703.up.
Childhood Cancers Sentence Syntax: limit 1 to childhood cancers
Command Syntax: ..c/pdqb Sentence Syntax: use pdqb
Change to PDQ Backfile from another database Sample PDQB Document
* CLOSED PROTOCOL: Not currently accepting new patients * Accession Number PDQP-010657 Update Code 9703 Cancer Name Osteogenic sarcoma Sarcoma, osteogenic Metastatic osteogenic sarcoma Osteogenic sarcoma, metastatic Osteosarcoma, metastatic Sarcoma, metastatic osteogenic Body site cancer -examples truncated- Identification Number MAYO-937502 NCI-V96-1075 Protocol Name Phase II Study of Ifosfamide/Mitomycin/Doxorubicin/Cisplatin plus GM-CSF in Advanced Sarcomas or Mesotheliomas (Summary Last Modified 02/97). Protocol Status Date Activated: 940523 Date Closed: 960808. Type of Protocol treatment clinical trial. Phase Phase II study. Therapy Modality Chemotherapy. Drug Identifiers Cisplatin Cisplatin/doxorubicin/GM-CSF/ifosfamide/mitomycin Cisplatin/doxorubicin/ifosfamide/mitomycin Doxorubicin Granulocyte-macrophage colony-stimulating factor Ifosfamide Mercaptoethane sulfonate Mitomycin -example truncated- Abstract OBJECTIVES: I. Assess the therapeutic effectiveness of ifosfamide, mitomycin, doxorubicin, and cisplatin (I-MAP) plus GM-CSF in patients with advanced sarcomas. II. Observe, preliminarily, the activity of I-MAP plus GM-CSF in patients with mesotheliomas. PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed advanced sarcoma or mesothelioma for which no known standard curative therapy exists Measurable or evaluable disease --Prior/Concurrent Therapy-- No prior cancer chemotherapy (with the exception of 1 new single-agent trial) No prior radiotherapy (except to distal extremity sites) - sample truncated - Detail of Protocol WARNING: Many protocols are potentially hazardous, are intended only for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this protocol should be consulted before using this protocol. Dose and schedule modifications are required for patients who develop gastrointestinal, hematologic, neurologic, and biochemical (renal, hepatic, etc.) and/or other abnormalities after the administration of therapy. Additionally, Federal regulations for the protection of human subjects require approval of clinical trials by your local Institutional Review Board. PROTOCOL OUTLINE: Patients are treated with subcutaneous GM-CSF for 4 days followed 3 -sample truncated- Lead Organizations Lead Organization: Mayo Clinic Cancer Center Local ID Number: MAYO-937502 Chairmen: John H. Edmonson 507-284-8413.
Some material in the PDQ database is from copyrighted publications of the respective copyright claimants. Users of the database are referred to the publication data appearing in the bibliographic citations, as well as to the copyright notices appearing in the original publication, all of which are hereby incorporated by reference. The NCI represents that PDQ is formulated with a reasonable standard of care. Except for this representation, NCI makes no representations or warranties, express or implied, including any implied warranty of merchantability or fitness for a particular purpose, with respect to PDQ. The documents contained in PDQ may be retained for personal or educational use only. Information should not be edited or modified. Any resale or redistribution of all or portions of the information is not permitted.
Because use of the PDQ database for insurance reimbursement decisions is contrary to the nature of the database, which is designed as a research tool and not to reflect all possible treatment options, customers agree to not make the database available to users who wish to use it for reimbursement decision purposes.
Revised 7 July, 1998